Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma Tetsuya Isaka, MD, Haruhiko Nakayama, MD, PhD,

Slides:

Advertisements

Similar presentations

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Advertisements

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Results of Coronary Artery Endarterectomy and Coronary Artery Bypass Grafting for Diffuse Coronary Artery Disease Srikrishna Sirivella, MD, Isaac Gielchinsky,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer

Thomas J. Birdas, MD, Richard P. M

Long-Term Survival of Patients With pN2 Lung Cancer According to the Pattern of Lymphatic Spread Antoine Legras, MD, Pierre Mordant, MD, PhD, Alex Arame,

Complete Metabolic Response Is Not Uniformly Predictive of Complete Pathologic Response After Induction Therapy for Esophageal Cancer Brendon M. Stiles,

Masatsugu Hamaji, MD, Stephen D. Cassivi, MD, K

Constantin Stefanidis, MD, Albert M

Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations Tae Jung Kim, MD, PhD, Choon-Taek.

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Suspected Aerogenous Lung Metastases From Nasopharyngeal Cancer

Robert E. Merritt, MD, Richard I. Whyte, MD, Nicole T

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

The Model for End-Stage Liver Disease (MELD) Predicts Early and Late Outcomes of Cardiovascular Operations in Patients With Liver Cirrhosis Naoto Morimoto,

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Jong Ho Cho, MD, Masatsugu Hamaji, MD, Mark S. Allen, MD, Stephen D

Risk Factors for Lymph Node Metastases and Prognosticators of Survival in Patients Undergoing Pulmonary Metastasectomy for Colorectal Cancer Servet Bölükbas,

Hanan A. Tanash, PhD, Gerdt C. Riise, PhD, Magnus P

Linetta B. Koppert, MD, PhD, Albertus N. van Geel, MD, PhD, Titia E

Prognostic Predictors in Non-Small Cell Lung Cancer Patients Undergoing Intentional Segmentectomy Terumoto Koike, MD, PhD, Teruaki Koike, MD, PhD, Yasushi.

Brendon M. Stiles, MD, Farooq Mirza, MD, Jeffrey L. Port, MD, Paul C

Michelle C. Ellis, MD, Brian S. Diggs, PhD, John T. Vetto, MD, Paul H

Outcome of Esophagectomy for Cancer in Elderly Patients

Pulmonary Resection in the Treatment of Multidrug-Resistant Tuberculosis: A Retrospective Study of 56 Cases Haifeng Wang, MM, Hongsheng Lin, MM, Gening.

Readmission to Intensive Care Unit After Initial Recovery From Major Thoracic Oncology Surgery Suk-Won Song, MD, Hyun-Sung Lee, MD, PhD, Jae-Hyun Kim,

Demographic, Psychosocial, and Behavioral Factors Associated With Survival After Heart Transplantation Steven A. Farmer, MD, PhD, Kathleen L. Grady,

Long-Term Outcomes After Surgical Resection of Pulmonary Metastases From Colorectal Cancer Hisashi Suzuki, MD, PhD, Moriyuki Kiyoshima, MD, Miyuki Kitahara,

Thomas J. Birdas, MD, Richard P. M

Who Do You Say You Are? The Annals of Thoracic Surgery

Influence of Cigarette Smoking on Survival and Tumor Invasiveness in Clinical Stage IA Lung Adenocarcinoma Ryo Maeda, MD, Junji Yoshida, MD, Genichiro.

Use of Amiodarone After Major Lung Resection

Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma Takashi.

Relation Between Thin-Section Computed Tomography and Clinical Findings of Mucinous Adenocarcinoma Hajime Watanabe, MD, Haruhiro Saito, MD, Tomoyuki.

Smoking Status as a Prognostic Factor in Patients with Stage I Pulmonary Adenocarcinoma Ichiro Yoshino, MD, PhD, Daigo Kawano, MD, Taro Oba, MD, Koji.

Survival After Surgery for Pathologic Stage IA Non-Small Cell Lung Cancer Associated With Idiopathic Pulmonary Fibrosis Yuichi Saito, MD, Yasuyuki Kawai,

Inderpal S. Sarkaria, MD, Maureen F

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma Gouji Toyokawa, PhD, Kazuki Takada,

Surgical Therapy for Bilateral Multiple Primary Lung Cancer

John M. Stulak, MD, Joseph A. Dearani, MD, Harold M

Heterogeneity of Tumor Sizes in Multiple Pulmonary Metastases of Colorectal Cancer as a Prognostic Factor Tomohiro Maniwa, MD, Keita Mori, PhD, Yasuhisa.

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko.

Editorial Board, January 2010

Severe Two-Vessel Ostial Stenosis of the Main Coronary Arteries in a Patient With Transposition of the Great Arteries After an Arterial Switch Operation

Comparison of Prognosis of Solid and Part-Solid Node-Negative Adenocarcinoma With the Same Invasive Component Size Kyung Wook Shin, MD, Sukki Cho, MD,

Completely Thrombosed Tricuspid Pouch Mimicking a Cardiac Tumor

Arman Kilic, BS, Matthew J. Schuchert, MD, Brian L

The Unifocal Bilateral Bidirectional Cavopulmonary Anastomosis

Prognostic Significance of Aberrant Methylation of Solute Carrier Gene Family 5A8 in Lung Adenocarcinoma Koei Ikeda, MD, PhD, Kenji Shiraishi, MD, PhD,

Genetic Syndromes and Outcome After Surgical Repair of Pulmonary Atresia and Ventricular Septal Defect Meng-Yu Chen, MD, Shuenn-Nan Chiu, MD, PhD, Jou-Kou.

Paul Urbanski, MD, PhD The Annals of Thoracic Surgery

Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer? Anna Lee, MD, MPH, Andrew T.

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study Hans Rostad, MD, PhD, Trond-Eirik Strand, MD, Anne Naalsund, MD, Jarle Norstein,

Limited Resection for Noninvasive Bronchioloalveolar Carcinoma Diagnosed by Intraoperative Pathologic Examination Terumoto Koike, MD, Ken-ichi Togashi,

Pulmonary Embolectomy for Acute Massive Pulmonary Embolism

Relevance of Lymph Node Micrometastases in Radically Resected Endobronchial Carcinoid Tumors Tommaso Claudio Mineo, MD, Gianluca Guggino, MD, Davide.

Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,

Role of Positron Emission Tomography/Computed Tomography Findings for Adjuvant Chemotherapy Indications in Stage T1b-2aN0M0 Lung Adenocarcinoma Shinsuke.

Prognostic Role of Positron Emission Tomography and High-Resolution Computed Tomography in Clinical Stage IA Lung Adenocarcinoma Hirofumi Uehara, MD,

Increased Rehospitalization Rate After Coronary Bypass Operation for Acute Coronary Syndrome: A Prospective Study in 200 Patients Staffan Bjessmo, MD,

Late Consequences of a Much Earlier Decision

Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma Tomoharu Yoshiya, MD, Takahiro Mimae, MD, PhD, Yasuhiro.

The Impact of New Technology on Cardiothoracic Surgical Practice

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Subpleural Honeycombing on High Resolution Computed Tomography is Risk Factor for Fatal Pneumonitis Hiroyuki Ito, MD, Haruhiko Nakayama, MD, Masahiro.

Presentation transcript:

Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma Tetsuya Isaka, MD, Haruhiko Nakayama, MD, PhD, Tomoyuki Yokose, MD, PhD, Hiroyuki Ito, MD, PhD, Yohei Miyagi, MD, PhD, Tomohiko Matsuzaki, MD, Masashi Nagata, MD, Hideyuki Furumoto, MD, Teppei Nishii, MD, Kayoko Katayama, PhD, Kouzo Yamada, MD, PhD, Munetaka Masuda, MD, PhD The Annals of Thoracic Surgery Volume 102, Issue 6, Pages 1821-1828 (December 2016) DOI: 10.1016/j.athoracsur.2016.06.001 Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 No significant differences were found in (A) disease-free survival (p = 0.280) or (B) overall survival (p = 0.564) between patients with mutated (Mt, solid line) or wild-type (Wt, dotted line) epidermal growth factor receptor (EGFR). The Annals of Thoracic Surgery 2016 102, 1821-1828DOI: (10.1016/j.athoracsur.2016.06.001) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 (A) The disease-free survival of pN1-N2 patients with exon deletion 19 (Ex19, dotted line) was significantly better (p = 0.001) than that of pN1-N2 patients with exon 21 L858R point mutation (Ex21, solid line). (B) The overall survival of pN1-N2 patients with Ex19 was better than that of pN1-N2 patients with Ex21, although this was not statistically significant (p = 0.123). The Annals of Thoracic Surgery 2016 102, 1821-1828DOI: (10.1016/j.athoracsur.2016.06.001) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 The (A) disease-free interval and (B) median survival time of pN1 patients with exon deletion 19 (Ex19, dotted line) were significantly longer compared with those of pN1 patients with exon 21 L858R point mutation (Ex21, solid line; p = 0.003 and p = 0.022, respectively). The Annals of Thoracic Surgery 2016 102, 1821-1828DOI: (10.1016/j.athoracsur.2016.06.001) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 4 (A) The disease-free interval of pN2 patients with exon 19 deletion (Ex19, dotted line) was longer than that of pN2 patients with exon 21 L858R point mutation (Ex21, solid line), although this was not statistically significant (p = 0.109). (B) No significant difference was found in median survival time between pN2 patients with Ex19 and pN2 patients with Ex21 (p = 0.856). The Annals of Thoracic Surgery 2016 102, 1821-1828DOI: (10.1016/j.athoracsur.2016.06.001) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions